[A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy]. 2009

Sachiko Kiyoto, and Fumikata Hara, and Shozo Osumi, and Daisuke Takabatake, and Seiki Takashima, and Kenjiro Aogi, and Shigemitsu Takashima
Dept. of Breast Oncology, Shikoku Cancer Center.

A 5 6-year-old woman, who underwent breast-conserving surgery and radiation (60 Gy) therapy in July, 1992, at the age of 40, was diagnosed with pT1aN0M0, pStage I. She was administered tamoxifen (TAM) as adjuvant therapy. However, she underwent microdochectomy for DCIS in her contralateral breast in June, 1998. TAM was given till August, 1999. In June, 2006, at the age of 54, 14 years after initial surgery, CT revealed extensive liver masses which were diagnosed as liver metastasis by liver biopsy. Receptor status was positive for ER and PgR, and negative for HER2. AC was started as a first-line chemotherapy ( 4 courses), but did not prove effective. She refused second-line chemotherapy, so letrozole was selected, and subsequently resulted in PR of the liver metastasis. However, 8 months later, with a liver metastasis relapse, exemestane followed by tamoxifen, medroxyprogesterone acetate, and high-dose toremifene were administered sequentially, resulting in long-time disease control. In conclusion, endocrine therapy might be an effective option even in a visceral crisis, if metastatic tumors have showed slow growth and there is positive hormone receptor status.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008525 Medroxyprogesterone A synthetic progestational hormone used in veterinary practice as an estrus regulator. (6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione,Methylhydroxyprogesterone,Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-,17 alpha-Hydroxy-6 alpha-Methylprogesterone,Adgyn Medro,17 alpha Hydroxy 6 alpha Methylprogesterone
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Sachiko Kiyoto, and Fumikata Hara, and Shozo Osumi, and Daisuke Takabatake, and Seiki Takashima, and Kenjiro Aogi, and Shigemitsu Takashima
December 2020, Gan to kagaku ryoho. Cancer & chemotherapy,
Sachiko Kiyoto, and Fumikata Hara, and Shozo Osumi, and Daisuke Takabatake, and Seiki Takashima, and Kenjiro Aogi, and Shigemitsu Takashima
September 1985, Gan no rinsho. Japan journal of cancer clinics,
Sachiko Kiyoto, and Fumikata Hara, and Shozo Osumi, and Daisuke Takabatake, and Seiki Takashima, and Kenjiro Aogi, and Shigemitsu Takashima
February 2017, Gan to kagaku ryoho. Cancer & chemotherapy,
Sachiko Kiyoto, and Fumikata Hara, and Shozo Osumi, and Daisuke Takabatake, and Seiki Takashima, and Kenjiro Aogi, and Shigemitsu Takashima
April 1999, Breast cancer (Tokyo, Japan),
Sachiko Kiyoto, and Fumikata Hara, and Shozo Osumi, and Daisuke Takabatake, and Seiki Takashima, and Kenjiro Aogi, and Shigemitsu Takashima
November 2012, Gan to kagaku ryoho. Cancer & chemotherapy,
Sachiko Kiyoto, and Fumikata Hara, and Shozo Osumi, and Daisuke Takabatake, and Seiki Takashima, and Kenjiro Aogi, and Shigemitsu Takashima
November 2017, Gan to kagaku ryoho. Cancer & chemotherapy,
Sachiko Kiyoto, and Fumikata Hara, and Shozo Osumi, and Daisuke Takabatake, and Seiki Takashima, and Kenjiro Aogi, and Shigemitsu Takashima
November 2016, Gan to kagaku ryoho. Cancer & chemotherapy,
Sachiko Kiyoto, and Fumikata Hara, and Shozo Osumi, and Daisuke Takabatake, and Seiki Takashima, and Kenjiro Aogi, and Shigemitsu Takashima
October 2015, Oncology letters,
Sachiko Kiyoto, and Fumikata Hara, and Shozo Osumi, and Daisuke Takabatake, and Seiki Takashima, and Kenjiro Aogi, and Shigemitsu Takashima
December 2023, Gan to kagaku ryoho. Cancer & chemotherapy,
Sachiko Kiyoto, and Fumikata Hara, and Shozo Osumi, and Daisuke Takabatake, and Seiki Takashima, and Kenjiro Aogi, and Shigemitsu Takashima
January 2006, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!